Oct 11, 2018
Orchard files for USD173 Million IPO to run pivotal gene therapy trials Orchard Therapeutics, Transatlantic biotech, has filed to raise USD 173 million in an IPO. This will lead it to take three gene therapies through the clinic. Orchard recognised itself as one of the broadest clinical-phase gene therapy pipelines ...
Read More...
Jan 06, 2015
Gene Therapy: The “Big Value” Market! Gene therapy has been under scientific research for over 2 decades, but viable therapies have yet to gain commercial acceptance due to safety and delivery-related issues. However, Pfizer’s move and some other recent developments in the industry suggest that the therapy may be ...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper